

1644

PATENT
Docket No. 17282CIP(AP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: Steward et al.)	Group Art Unit: 1644
)	
Serial No.: 09/548,409)	Examiner: Nolan, P.
Conf. No.: 7255)	
Filed: April 13, 2000)	
)	
For: Compositions and Methods)	
For the Treatment of Pancreatitis)	

RECEIVED

MAY 28 2003

TRANSMITTAL SHEET

TECH CENTER 1600/2900

Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment in the above-identified application. Enclosed are:

- 1) Return/Stamped Postcard
- 2) Transmittal Sheet/Certificate of Mailing
- 3) Reply and Amendment (5 pages)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as FIRST CLASS MAIL in an envelope addressed to: Mail Stop Final Amendment-Non-Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

5/21/2003

(Date of Deposit)

5/21/2003

Date of Signature

Bonnie Ferguson
Name of person mailing correspondence

Bonnie Ferguson
Signature

The fee has been calculated as shown below:

CLAIMS AS FILED

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE	
Total Claims	12	MINUS	20	= 0 ×	\$18	= \$0.00	
Independent Claims	1	MINUS	3	= 0 ×	\$84	= \$0.00	
If application has been amended to contain multiple dependent claim(s), then add					\$280	= \$0.00	
(Select only one)					one month	\$110	= \$0.00
Time Extension Fees:					two months	\$410	= \$
					three months	\$930	= \$
					four months	\$1,450	= \$*
					TOTAL ADDITIONAL FEE FOR THIS AMENDMENT	\$ 00.00	

- () A check in the amount of \$* is enclosed (place fee in here i.e., petition, excess claims, etc.)
(x) The Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 (associated with petition fees or excess claim fees) which may be required, or credit any overpayment to Deposit Account No. 01-0885. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

Date: 5/21/03

Signature: Carlos A. Fisher

Carlos A. Fisher
Registration No. 36,510
Legal Department, T2-7H
ALLERGAN, INC.
2525 Dupont Drive
Irvine, CA 92612
Telephone: (714) 246-4920
Fax: (714) 246-4249

O I P E
MAY 21 2003
PATENT & TRADEMARK OFFICE
Docket No. 17282 CIP

20/E NE
PATENT
ES-5-29-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Steward et al.) Group Art Unit: 1644
Serial No.: 09/548,409)
Conf. No.: 7255) Examiner: Nolan, P.
Filed: April 13, 2000)
For: Compositions and Methods)
For the Treatment of Pancreatitis)

AMENDMENT B

Commissioner for Patents
Alexandria, VA 22313-1450

RECEIVED
MAY 28 2003
TECH CENTER 1600/2900

Dear Sir:

This communication is in reply to the Office Action mailed February 24, 2003.

Applicants have the following comments.

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Final Amendment-Non - Fee; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date of Deposit: 5/21/2003 Person making Deposit: Bonnie Ferguson

Signature: Bonnie Ferguson Date of Signature: 5/21/2003

AMENDMENT

1. (Currently amended) A composition for the treatment of acute pancreatitis in a mammal comprising, a first element comprising a binding element able to specifically bind a pancreatic acinar cell CCK receptor under physiological conditions, a second element comprising a translocation element derived from a clostridial neurotoxin heavy chain able to facilitate the transfer of a polypeptide across a vesicular membrane, and a third element comprising a therapeutic element derived from a clostridial neurotoxin light chain[]able, when present in the cytoplasm of a pancreatic cell, to inhibit enzymatic secretion by said pancreatic cell.
2. (Cancelled)
3. (Original) The composition of claim 1 wherein said therapeutic element will cleave a SNARE protein and cleavage of said SNARE protein inhibits said secretion.
4. (Original) The composition of claim 3 wherein said SNARE protein is selected from the group consisting of syntaxin, SNAP-25 and VAMP.
5. (Original) The composition of claim 2 wherein said therapeutic element will cleave a SNARE protein, wherein cleavage of said SNARE protein inhibits said secretion.
6. (Original) The composition of claim 5 wherein said SNARE protein is selected from the group consisting of syntaxin, SNAP-25 and VAMP.
7. (Original) The composition of claim 5 wherein said CCK receptor is the human CCK A receptor.
8. (Original) The composition of claim 7 wherein the binding element of said

therapeutic polypeptide comprises a human CCK A amino acid sequence modified by the presence of a C-terminal amidated phenylalanine and a sulfated tyrosine at the position 7 residues from the carboxyl terminus.

9. (Original) The composition of claim 8 wherein said CCK A amino acid sequence comprises SEQ ID NO: 6.

10. (Original) The composition of claim 9 wherein said CCK A amino acid sequence comprises SEQ ID NO: 5.

11. (Original) The composition of claim 9 wherein said CCK A amino acid sequence comprises SEQ ID NO: 4.

12. (Original) The composition of claim 9 wherein said CCK A amino acid sequence comprises SEQ ID NO: 3.

13. (Original) The composition of claim 9 wherein said CCK A amino acid sequence comprises SEQ ID NO: 2.

14-19. (Withdrawn)